<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04635384</url>
  </required_header>
  <id_info>
    <org_study_id>SN-C-00014</org_study_id>
    <nct_id>NCT04635384</nct_id>
  </id_info>
  <brief_title>Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test</brief_title>
  <acronym>ACROBAT</acronym>
  <official_title>Assessment of Chimerism and Relapse Post Bone Marrow/HCT Transplant Using AlloHeme Test (ACROBAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CareDx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CareDx</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AlloHeme is a chimerism test service that utilizes NGS technology to analyze SNP loci to&#xD;
      quantify donor and recipient cells by measuring genomic DNA. Before transplant, patient and&#xD;
      donor peripheral blood sample will be collected to identify informative marker for routine&#xD;
      chimerism testing and baseline establishment for AlloHeme. Post-transplant blood or bone&#xD;
      marrow samples are obtained and compared to the baseline sample profiles to calculate %&#xD;
      chimerism of recipient cells in the blood and/or bone marrow samples. Cell selection from&#xD;
      blood and bone marrow samples is applied to evaluate chimerism in specific cell subtypes that&#xD;
      are relevant to AML and MDS diseases (CD3+ T lymphocytes, CD33+ Myeloid cells and CD15+&#xD;
      Granulocyte cell subtypes from blood and CD34+ hematopoietic stem cells from bone marrow).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The test will be started from month 1 post HCT and will be performed bi-weekly up to month 3,&#xD;
      monthly from month 4-6 and quarterly from month 9 to year 2 for total 15 visits. During each&#xD;
      visit, about 18 ml (3.6 teaspoons) of whole blood will be collected into 3 pink BD Hemogard&#xD;
      tubes with K2 EDTA additive. In addition to blood collection, the subject will be asked to&#xD;
      provide 3ml or 0.6 teaspoon of bone marrow specimens during the routine visits on Day&#xD;
      100(month 3), Day 180 and Day 360 for use in this research study. When bone marrow study is&#xD;
      performed, marrow specimen will be collected for AlloHeme test at central lab. Standard&#xD;
      chimerism assessment, bone marrow study and MRD test will be performed at each participated&#xD;
      institution lab as clinically indicated and based on treating physician's discretion. Method&#xD;
      of standard of care chimerism and MRD assessment will be based on each institutional standard&#xD;
      protocol. Data related to AlloHeme test, clinical outcomes, PHI and all standard of care of&#xD;
      patient management information will be collected from medical records. During the Baseline&#xD;
      and pre transplant the following clinical data will be collected: sex, age, donor and&#xD;
      recipient demographic, chemotherapy, remission status pre-transplant, donor type, HLA, stem&#xD;
      cell source, conditioning regimen type and intensity, cytogenetics test, minimal residual&#xD;
      disease, chimerism, T cell depletion and GVHD protocol. Following transplantation, clinical&#xD;
      events including death, relapse, second allo-HSCT, DLI as well as the events that impact the&#xD;
      chimerism like tapering IST, GVHD and infection will be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the association between increased mixed chimerism (iMC) detected by AlloHeme and post-transplant relapse in patients with acute leukemia and myelodysplastic syndrome.</measure>
    <time_frame>Jan-2022</time_frame>
    <description>Comparison of cumulative incidence of relapse post-transplant of patients with increased mixed chimerism (iMC) vs. complete chimerism (CC) vs. stable/decrease mixed chimerism (sMC/dMC) detected by AlloHeme.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the association of microchimerism detected by AlloHeme on post-transplant relapse in patients with acute leukemia and myelodysplastic syndrome</measure>
    <time_frame>Jan-2022</time_frame>
    <description>Comparison of cumulative incidence of relapse post-transplant of patients with microchimerism vs. CC detected by AlloHeme</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the association between an iMC detected by AlloHeme and disease-free survival (DFS) post-transplant in patients with acute leukemia and myelodysplastic syndrome</measure>
    <time_frame>Jan-2022</time_frame>
    <description>Comparison of DFS post-transplant in patients with iMC vs. complete chimerism (CC) vs. stable/decrease mixed chimerism (sMC/dMC) detected by AlloHeme.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the correlation between peripheral blood chimerism detected by AlloHeme and post-transplant measurable residual disease (MRD) status in patients with acute leukemia and myelodysplastic syndrome</measure>
    <time_frame>Jan-2022</time_frame>
    <description>Statistical correlation and agreement of peripheral blood donor chimerism quantitatively detected by AlloHeme and post-transplant MRD from bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the performance of post-transplant chimerism measured by AlloHeme versus STR-PCR method for post-transplant relapse prediction in patients with acute leukemia and myelodysplastic syndrome.</measure>
    <time_frame>Jan-2022</time_frame>
    <description>Comparison of performance AlloHeme versus STR-PCR method for post-transplant relapse prediction including Sensitivity Specificity, Positive predictive value, negative predictive value, AuROC</description>
  </secondary_outcome>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      AlloHeme is a chimerism test service that utilizes NGS technology to analyze SNP loci to&#xD;
      quantify donor and recipient cells by measuring genomic DNA. Before transplant, patient and&#xD;
      donor peripheral blood sample will be collected to identify informative marker for routine&#xD;
      chimerism testing and baseline establishment for AlloHeme. Post-transplant blood or bone&#xD;
      marrow samples are obtained and compared to the baseline sample profiles to calculate %&#xD;
      chimerism of recipient cells in the blood and/or bone marrow samples.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants aged &gt; 18 years old with a diagnosis of AML, ALL, and MDS who will undergo an&#xD;
        Allo-HCT will be invited to participate and enrolled into the study at the time initial&#xD;
        transplant evaluation or at any time before admission for transplantation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, aged 18 years or above.&#xD;
&#xD;
          -  The patient must have one of the following diseases: AML, ALL or MDS&#xD;
&#xD;
          -  Eligible for allogeneic hematopoietic stem cell transplant&#xD;
&#xD;
          -  Subjects must receive an Allo-HCT from an HLA matched related or unrelated donor or&#xD;
             haploidentical donor&#xD;
&#xD;
          -  Myeloablative or reduced intensity/non-myeloablative conditioning&#xD;
&#xD;
          -  Any GVHD prophylaxis regimen including post-transplantation cyclophosphamide-based or&#xD;
             conventional regimen&#xD;
&#xD;
          -  The subject must be enrolled prior to Allo-HCT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The participant may not enter the study if ANY of the following apply:&#xD;
&#xD;
          -  Has history of prior Allo-HCT&#xD;
&#xD;
          -  T cell depleted transplant (Including in vivo and ex vivo T cell depletion)&#xD;
&#xD;
          -  Inability to comply with medical recommendations or follow-up&#xD;
&#xD;
          -  Donor is identical twin&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashish Kothari, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>CareDx</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashish Kothari, M.D.</last_name>
    <phone>+1 (415) 287-2362</phone>
    <email>akothari@caredx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sean Sana, M.D.,</last_name>
    <email>ssana@caredx.com</email>
  </overall_contact_backup>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>ALL</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

